ProCE Banner Activity

Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

Podcast Episodes
Listen to Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss the implications of recent trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).

Released: August 31, 2020

Expiration: August 30, 2021

Share

Faculty

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

Jennifer R. Brown

Jennifer R. Brown, MD, PhD

Assistant Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Attending Physician, Lymphoma Program
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD, has disclosed the he has received funds for research support from Celgene, Genentech, Janssen, and TG Therapeutics; consulting fees from AbbVie, Ascentage, BeiGene, Genentech, Janssen, and Pharmacyclics; and fees for non-CME/CE services from AbbVie, Genentech, Janssen, and Pharmacyclics.

Jennifer R. Brown, MD, PhD

Assistant Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Attending Physician, Lymphoma Program
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Jennifer R. Brown, MD, PhD, has disclosed that she has received funds for research support from Gilead, Loxo/Lilly, Sun Pharmaceuticals and Verastem; consulting fees from Acerta/AstraZeneca, BeiGene, Catapult, Eli Lilly & Company, Juno/Celgene, Morphosys AG, MEI Pharma, Nextcea, Novartis, Octapharma, Pfizer, Rigel, and Verastem; and fees for non-CME/CE services from Janssen.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Colleen Heffner, PharmD

Colleen Heffner, PharmD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.